COVID-19 Pre-Vaccination Additional and Temporary Screening Questions

Effective 31/03/2021 – Updated 09/04/2021

Facility: .........................................................

To be completed by the person (or substitute decision-maker/parent/legal guardian/other person) to be vaccinated.

Additional Vaccination Screening Questions

This form is effective from the 31 March 2021 until superseded or rescinded.

This form should be used in conjunction with the pre-vaccination screening questions in the Queensland COVID-19 Vaccine Management System (QCVMS) application or in the COVID-19 Pre-Vaccination Screening Questions form.

The Australian Technical Advisory Group on Immunisation (ATAGI) recommends that vaccination with any COVID-19 vaccine should be deferred for people who have a history of the below rare conditions. Further ATAGI information (www.health.gov.au/news/atagi-statement-on-astrazeneca-vaccine-in-response-to-new-vaccine-safety-concerns – 08/04/2021) recommends that the Pfizer (Comirnaty) vaccine is preferred over COVID-19 Vaccine AstraZeneca in adults aged under 50 years. If you answer YES to any of the below questions, please raise with the relevant health worker at your vaccination site prior to your vaccination. This is a precautionary measure until further information is available from overseas investigations.

Do you have a previous confirmed history of cerebral venous sinus thrombosis (CVST) or splanchnic vein thrombosis (SVT)?

☐ Yes ☐ No

Do you have a previous confirmed medical history of heparin induced thrombocytopenia (HIT)?

☐ Yes ☐ No

Are you younger than 50 years of age?

☐ Yes ☐ No

Additional Notes For Clinic Health Care Workers

These recent precautions are not currently listed in the vaccine product information and the questions are not incorporated into the QCVMS application.

If any of the above three questions are answered as YES please enter this information manually into the ‘Clinician Comment’ section at the Check-in screen before cancelling/amending (or proceeding with) the appointment as per a clinical decision. Note that any person aged under 50 years wishing to receive the AstraZeneca vaccine, can choose to do so, however should be fully informed about thrombosis in combination with thrombocytopenia as a rare but serious side effect before vaccination. If the appointment is cancelled, please keep a record of the consumer’s health and contact information for follow up and recall should the above advisory be changed.

Please advise the consumer to periodically refer to the Commonwealth Health website: www.health.gov.au/news for any updates to this information and re-book as necessary.

The Therapeutic Goods Administration and ATAGI have reviewed information in relation to general thromboembolic disorders after vaccination and considers that there is no evidence of a higher risk of common thrombotic disease after COVID-19 vaccination in people with a history of clotting conditions. ATAGI continues to recommend vaccination with either AstraZeneca or Pfizer (Comirnaty) COVID-19 vaccines in people with a history of the below conditions:

- deep venous thrombosis and/or pulmonary embolism
- risk factors for thrombosis (such as use of oral contraceptives or smoking)
- thrombocytopenia (low platelets that can occur with clotting conditions)
- known thrombophilic disorders
- cardiovascular disease (such as myocardial infarction or stroke)
- on anticoagulants (e.g. warfarin).

Health Worker Comments Only

Proceed with vaccination? ☐ Yes ☐ No

Vaccine type recommended? ☐ AstraZeneca (ChAdOx1-S) ☐ Pfizer (Comirnaty)

Comments:

Clinician name: .......................... Designation: .......................... Signature: .......................... Date: ..........................

This document is current at the date of publication. PRINTED COPIES ARE UNCONTROLLED. TO ensure you have the most up-to-date copy please visit: https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/novel-coronavirus-qld-clinicians/covid-19-vaccination-information-for-healthcare-workers.